Rosemary Barrett
YOU?
Author Swipe
View article: Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma Open
Uveal melanoma (UM) is the most common primary intraocular malignancy in the adult eye. Despite the aggressive local management of primary UM, the development of metastases is common with no effective treatment options for metastatic disea…
View article: Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma
Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma Open
Unesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive sur…
View article: Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 5F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 5F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 5F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Supplementary Table 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Table 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Table 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Patient Data from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Patient Data from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Patient information corresponding to patients included in Supplementary Figure 5.
View article: Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 4 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 4 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 4 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Fig. S4 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S4 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S4 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Supplementary Fig. S6 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S6 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S6 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Data from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Data from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
For a subpopulation of acute myeloid leukemia (AML) patients, the constitutively activated tyrosine kinase, mutant FLT3, has emerged as a promising target for therapy. The development of drug resistance, however, is a growing concern for m…
View article: Supplementary Figure 6 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 6 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 6 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Fig. S5 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S5 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S5 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Supplementary Figure 4 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 4 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 4 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Data from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Data from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Clinical studies of patients with chronic myeloid leukemia revealed that a common pattern of response is a dramatic fall in the circulating population of blast cells, with a minimal or delayed decrease in marrow blasts, suggesting a protec…
View article: Supplementary Figure 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 5A-5E from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 5A-5E from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 5A-5E from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 6 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 6 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 6 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Fig. S6 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Supplementary Fig. S6 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Open
Supplementary Fig. S6 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
View article: Data from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Data from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
For a subpopulation of acute myeloid leukemia (AML) patients, the constitutively activated tyrosine kinase, mutant FLT3, has emerged as a promising target for therapy. The development of drug resistance, however, is a growing concern for m…